Research programme: second generation zebularine molecules - Idogen

Drug Profile

Research programme: second generation zebularine molecules - Idogen

Latest Information Update: 29 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Idogen; Lund University
  • Developer Idogen; Lund University; University of Oxford
  • Class Antineoplastics
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Diabetes mellitus; Rheumatoid arthritis

Most Recent Events

  • 23 Mar 2017 Idogen has a patent pending for its zebularine molecules technology in the US
  • 05 Dec 2016 Idogen has patent protection for additional aspects of using zebularine for the treatment of autoimmune diseases and rejection of transplanted organs in Europe
  • 20 Jul 2016 Preclinical trials in Rheumatoid arthritis in Sweden (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top